A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate
暂无分享,去创建一个
Wenjiang J. Fu | R. Romero | D. Todem | O. Erez | T. Chaiworapongsa | R. Levine | S. Karumanchi | J. Espinoza | F. Gotsch | S. Mazaki‐Tovi | J. Kusanovic | R. Gomez | J. Nien | S. Edwin | Hwan Chung | Ananth A Karumanchi | A. Karumanchi
[1] S. Bhoola,et al. Adjuvant Chemotherapy in a Pregnant Woman With Endodermal Sinus Tumor of the Ovary , 2007, Obstetrics and gynecology.
[2] R. Romero,et al. Unexplained fetal death: Another anti-angiogenic state , 2007, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.
[3] B. Sibai,et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. , 2006, The New England journal of medicine.
[4] F. Epstein,et al. Circulating Angiogenic Factors and Placental Abruption , 2006, Obstetrics and gynecology.
[5] Donna D. Johnson,et al. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. , 2006, American journal of obstetrics and gynecology.
[6] E. Gratacós,et al. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. , 2006, American journal of obstetrics and gynecology.
[7] B. Sibai,et al. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. , 2006, American journal of obstetrics and gynecology.
[8] T. Libermann,et al. Soluble endoglin contributes to the pathogenesis of preeclampsia , 2006, Nature Medicine.
[9] H. Stepan,et al. Elevated sFlt1 level and preeclampsia with parvovirus-induced hydrops. , 2006, The New England journal of medicine.
[10] R. Romero,et al. A role of the anti-angiogenic factor sVEGFR-1 in the ‘mirror syndrome’ (Ballantyne's syndrome) , 2005, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.
[11] R. Rodrigo,et al. Screening test for preeclampsia through assessment of uteroplacental blood flow and biochemical markers of oxidative stress and endothelial dysfunction. , 2005, American journal of obstetrics and gynecology.
[12] T. Lyberg,et al. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. , 2005, European journal of obstetrics, gynecology, and reproductive biology.
[13] R. Ness,et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. , 2005, The Journal of clinical endocrinology and metabolism.
[14] I. Sargent,et al. Latest Advances in Understanding Preeclampsia , 2005, Science.
[15] R. Romero,et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia , 2005, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.
[16] S. Kōzuma,et al. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. , 2004, Endocrinology.
[17] A. Hunter,et al. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. , 2004, American journal of obstetrics and gynecology.
[18] G. PaolaViviani,et al. Curva nacional de distribución de peso al nacer según edad gestacional: Chile, 1993 a 2000 , 2004 .
[19] Napoleone Ferrara,et al. Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.
[20] R. Romero,et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. , 2004, American journal of obstetrics and gynecology.
[21] K. Nicolaides,et al. The role of uterine artery Doppler in predicting adverse pregnancy outcome. , 2004, Best practice & research. Clinical obstetrics & gynaecology.
[22] Johanna W Lampe,et al. Antibiotic use in relation to the risk of breast cancer , 2004, JAMA.
[23] Robert N. Taylor,et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. , 2004, The Journal of clinical endocrinology and metabolism.
[24] N. Bersinger,et al. Second‐ and third‐trimester serum levels of placental proteins in preeclampsia and small‐for‐gestational age pregnancies , 2004, Acta obstetricia et gynecologica Scandinavica.
[25] H. Augustin,et al. Prospective Analysis of Placenta Growth Factor (PlGF) Concentrations in the Plasma of Women with Normal Pregnancy and Pregnancies Complicated by Preeclampsia , 2004, Hypertension in pregnancy.
[26] J. Foidart,et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. , 2003, The Journal of clinical endocrinology and metabolism.
[27] T. Libermann,et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. , 2003, The Journal of clinical investigation.
[28] L. Claesson‐Welsh,et al. VEGF receptor signal transduction. , 2003, Science's STKE : signal transduction knowledge environment.
[29] Christoph Dehio,et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 , 2003, Nature Medicine.
[30] A. Luttun,et al. Placental growth factor and its receptor, vascular endothelial growth factor receptor‐1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders , 2003, Journal of thrombosis and haemostasis : JTH.
[31] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[32] Y. Taketani,et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. , 2003, The Journal of clinical endocrinology and metabolism.
[33] A. Luttun,et al. Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? , 2003, The Journal of clinical investigation.
[34] M. Maio,et al. Differential levels of soluble endoglin (CD105) in myeloid malignancies , 2003, Journal of cellular physiology.
[35] T. Mayhew. Fetoplacental angiogenesis during gestation is biphasic, longitudinal and occurs by proliferation and remodelling of vascular endothelial cells. , 2002, Placenta.
[36] L. Poston,et al. A longitudinal study of biochemical variables in women at risk of preeclampsia. , 2002, American journal of obstetrics and gynecology.
[37] N. Anim-Nyame,et al. Does endothelial cell activation occur with intrauterine growth restriction? , 2002, BJOG : an international journal of obstetrics and gynaecology.
[38] J. Roberts,et al. Recent Insights into the pathogenesis of pre-eclampsia. , 2002, Placenta.
[39] M. Goumans,et al. Balancing the activation state of the endothelium via two distinct TGF‐β type I receptors , 2002, The EMBO journal.
[40] K. Acharya,et al. Role of placenta growth factor in cardiovascular health. , 2002, Trends in cardiovascular medicine.
[41] P. Carmeliet,et al. Cell Type‐Specific Expression of Neuropilins in an MCA‐Occlusion Model in Mice Suggests a Potential Role in Post‐Ischemic Brain Remodeling , 2002, Journal of neuropathology and experimental neurology.
[42] S. Wiegand,et al. Hemochorial Placentation in the Primate: Expression of Vascular Endothelial Growth Factor, Angiopoietins, and Their Receptors Throughout Pregnancy1 , 2002, Biology of reproduction.
[43] K. Nicolaides,et al. Multicenter screening for pre‐eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation , 2001, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[44] C. Oudejans,et al. Plasma Placenta Growth Factor Levels in Midtrimester Pregnancies , 2001, Obstetrics and gynecology.
[45] Ana Ivelisse Avilés,et al. Linear Mixed Models for Longitudinal Data , 2001, Technometrics.
[46] M. Maio,et al. Endoglin: An accessory component of the TGF‐β‐binding receptor‐complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies , 2001, Journal of cellular physiology.
[47] H. Ho,et al. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. , 2001, American journal of obstetrics and gynecology.
[48] L. Poston,et al. Is oxidative stress involved in the aetiology of pre‐eclampsia? , 2001, Acta paediatrica (Oslo, Norway : 1992). Supplement.
[49] K. Nicolaides,et al. One‐Stage Screening for Pregnancy Complications by Color Doppler Assessment of the Uterine Arteries at 23 Weeks' Gestation , 2000, Obstetrics and gynecology.
[50] Stanley J. Wiegand,et al. Vascular-specific growth factors and blood vessel formation , 2000, Nature.
[51] P. Carmeliet. Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.
[52] M. Faas,et al. Etiology and pathogenesis of preeclampsia: current concepts. , 1999, American journal of obstetrics and gynecology.
[53] G. Yancopoulos,et al. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. , 1999, Genes & development.
[54] I. Sargent,et al. Preeclampsia: an excessive maternal inflammatory response to pregnancy. , 1999, American journal of obstetrics and gynecology.
[55] J. Wrana,et al. Endoglin Is an Accessory Protein That Interacts with the Signaling Receptor Complex of Multiple Members of the Transforming Growth Factor-β Superfamily* , 1999, The Journal of Biological Chemistry.
[56] L. Attisano,et al. Role of Endoglin in Cellular Responses to Transforming Growth Factor-β , 1998, The Journal of Biological Chemistry.
[57] A. N. Corps,et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. , 1998, Biology of reproduction.
[58] T. H. Wang,et al. Preeclampsia is associated with reduced serum levels of placenta growth factor. , 1998, American journal of obstetrics and gynecology.
[59] T. H. Wang,et al. Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. , 1997, Placenta.
[60] P. Lastres,et al. Endoglin modulates cellular responses to TGF-beta 1 , 1996, The Journal of cell biology.
[61] C. Lees,et al. Doppler ultralsound of the uterine arteries: the importance of bilateral notching in the prediction of pre‐eclampsia, placental abruption or delivery of a small‐for‐gestational‐age baby , 1996 .
[62] M. Cohen,et al. Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow. , 1995, Journal of immunology.
[63] A. Rigby,et al. Analysis of Longitudinal Data , 2003 .
[64] S. Campbell,et al. Doppler ultrasound screening as part of routine antenatal scanning: Prediction of pre‐eclampsia and intrauterine growth retardation , 1994, British journal of obstetrics and gynaecology.
[65] M. Letarte,et al. Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-beta binding protein of endothelial and stromal cells. , 1994, Endocrinology.
[66] S. Rockman,et al. Endoglin: a 180‐kD endothelial cell and macrophage restricted differentiation molecule , 1992, Clinical and experimental immunology.
[67] C. Cabañas,et al. Regulated expression on human macrophages of endoglin, an Arg‐Gly‐Asp‐containing surface antigen , 1992, European journal of immunology.
[68] S. Bewley,et al. Doppler velocimetry studies of the uterine artery in the early prediction of pre-eclampsia and intra-uterine growth retardation. , 1991, European journal of obstetrics, gynecology, and reproductive biology.
[69] Muni S. Srivastava,et al. Regression Analysis: Theory, Methods, and Applications , 1991 .
[70] A. Saalmüller,et al. Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow. , 1991, Leukemia.
[71] T. Musci,et al. Preeclampsia: an endothelial cell disorder. , 1989, American journal of obstetrics and gynecology.
[72] M. Letarte,et al. Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. , 1988, Journal of immunology.
[73] S. Zeger,et al. Longitudinal data analysis using generalized linear models , 1986 .
[74] M. J. Teague,et al. NEW DOPPLER TECHNIQUE FOR ASSESSING UTEROPLACENTAL BLOOD FLOW , 1983, The Lancet.
[75] M. Kenward,et al. An Introduction to the Bootstrap , 2007 .
[76] S. Thung. Urinary Placental Growth Factor and Risk of Preeclampsia , 2006 .
[77] F. Totzke,et al. Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors , 2004, Angiogenesis.
[78] R. Gomez,et al. [A national birth weight distribution curve according to gestational age in Chile from 1993 to 2000]. , 2004, Revista medica de Chile.
[79] Robert N. Taylor,et al. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. , 2003, American journal of obstetrics and gynecology.
[80] A. Luttun,et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 , 2002, Nature Medicine.
[81] D. Ruppert,et al. THE SANDWICH ( ROBUST COVARIANCE MATRIX ) ESTIMATOR , 1998 .
[82] J. V. van Mourik,et al. Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. , 1992, International immunology.
[83] H. White. Maximum Likelihood Estimation of Misspecified Models , 1982 .
[84] P. J. Huber. The behavior of maximum likelihood estimates under nonstandard conditions , 1967 .